Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling program is now being planned to further explore these findings. Shares are trading 11.11 per cent higher at 0.5 cents.
Adacel Technologies (ASX:ADA) has successfully retained the FAA contract for Tower Simulation System Support & Technical Refresh. The contract, valued at USD$59 million, will involve comprehensive maintenance and upgrades, and Adacel anticipates generating EBITDA between $4 million and $5 million in FY2025. Shares are trading 13.64 per cent higher at 50 cents.
Neurotech International (ASX:NTI) has announced that NTI164, the company's proprietary drug formulation derived from a unique cannabis strain with low THC, has been shown to reverse immune dysregulation in PANDAS/PANS children, as evidenced by genomic analysis. This suggests that the drug has the potential to improve the overall health and functional outcomes of children with these conditions. Shares are trading 7.35 per cent higher at 7.3 cents.
Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling program is now being planned to further explore these findings. Shares are trading 11.11 per cent higher at 0.5 cents.
阿德隆黄金（澳大利亚证券交易所股票代码：ADG）已聘请了一位新的勘探顾问来推进阿德隆黄金项目。初步的土壤采样显示出砷和锑的良好迹象，表明潜在的金矿化。目前正在计划一项钻探计划，以进一步探索这些发现。股价上涨11.11％，至0.5美分。
Adacel Technologies (ASX:ADA) has successfully retained the FAA contract for Tower Simulation System Support & Technical Refresh. The contract, valued at USD$59 million, will involve comprehensive maintenance and upgrades, and Adacel anticipates generating EBITDA between $4 million and $5 million in FY2025. Shares are trading 13.64 per cent higher at 50 cents.
Adacel Technologies（澳大利亚证券交易所股票代码：ADA）成功保留了美国联邦航空局的塔式仿真系统支持和技术更新合同。该合同价值5900万美元，将涉及全面的维护和升级，Adacel预计 FY2025 的息税折旧摊销前利润将在400万至500万美元之间。股价上涨13.64％，至50美分。
Neurotech International (ASX:NTI) has announced that NTI164, the company's proprietary drug formulation derived from a unique cannabis strain with low THC, has been shown to reverse immune dysregulation in PANDAS/PANS children, as evidenced by genomic analysis. This suggests that the drug has the potential to improve the overall health and functional outcomes of children with these conditions. Shares are trading 7.35 per cent higher at 7.3 cents.
Neurotech International（澳大利亚证券交易所股票代码：NTI）宣布，该公司的专有药物配方 NTI164 源自一种独特的低四氢大麻毒株，已被证明可以逆转PANDAS/PANS儿童的免疫失调，基因组分析证明了这一点。这表明该药物有可能改善患有这些疾病的儿童的整体健康和功能结果。股价上涨7.35％，至7.3美分。
